Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 13/20 | 0.59 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TOP1 | P11387 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TOP2A | P11388 | 3/20 | 0.57 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504817 | 0.89 | NQO2 (0.49) | NQO2PRMT1TDP1ALDH1A1TOP1 | |
| SCHEMBL3508193 | 0.89 | NQO2 (0.47) | NQO2PRMT1TDP1ALDH1A1TOP1 | |
| SCHEMBL394063 | 0.87 | NQO2 (0.46) | NQO2PRMT1TDP1ALDH1A1TOP1 | |
| SCHEMBL5491209 | 0.84 | PRMT1 (0.61) | NQO2PRMT1TDP1ALDH1A1TOP1 | |
| SCHEMBL5489119 | 0.84 | NQO2 (0.44) | NQO2PRMT1TDP1ALDH1A1TOP1 | |
| SCHEMBL4951247 | 0.81 | NQO2 (0.47) | NQO2PRMT1TDP1ALDH1A1TOP1 | |
| SCHEMBL399205 | 0.79 | ALDH1A1 (0.46) | NQO2PRMT1TDP1ALDH1A1TOP1 | |
| SCHEMBL12348299 | 0.79 | HSD17B10 (0.36) | PRMT1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL549233 | 0.77 | NQO2 (0.52) | NQO2PRMT1TDP1ALDH1A1TOP1 | |
| SCHEMBL3504227 | 0.77 | NQO2 (0.57) | NQO2PRMT1TDP1ALDH1A1TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242059-B1 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIV NORTH CAROLINA (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20040127721-A1 | Process for the synthesis of bis-aryl diamidoxime compounds | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2004-07-01 | — | — | US | disclosed |
| US-6649652-B2 | Hypotensive agents; hyperglycemic agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-11-18 | — | — | US | disclosed |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-15 | — | — | US | disclosed |
| US-6503940-B2 | Aids therapy | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-01-07 | — | — | US | disclosed |
| US-6486200-B1 | Prodrugs for antimicrobial amidines | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2002-11-26 | — | — | US | disclosed |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127721-A1 | Process for the synthesis of bis-aryl diamidoxime compounds | DDT, DAO, DDO | NQO2 339/4885PRMT1 3200/4885TDP1 1405/4885 |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | NQO2 396/4885PRMT1 1521/4885TDP1 2764/4885 |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | NQO2 396/4885PRMT1 1521/4885TDP1 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.